Lead Product(s) : Human Rho D Immune Globulin
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PRIVIGEN Granted Orphan-Drug Designation
Details : CSL Behring advances Ig clinical trial program to address need in treating serious autoimmune disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 02, 2020
Lead Product(s) : Human Rho D Immune Globulin
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : SAB Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
SAB Biotherapeutics Announces Research Collaboration With CSL Behring
Details : The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb™ platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : SAB Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration